C
12.02
-0.88 (-6.82%)
| Previous Close | 12.90 |
| Open | 12.88 |
| Volume | 1,381,557 |
| Avg. Volume (3M) | 488,512 |
| Market Cap | 699,895,808 |
| Price / Book | 1.19 |
| 52 Weeks Range | |
| Earnings Date | 12 Mar 2025 - 17 Mar 2025 |
| Diluted EPS (TTM) | -2.84 |
| Total Debt/Equity (MRQ) | 0.39% |
| Current Ratio (MRQ) | 24.46 |
| Operating Cash Flow (TTM) | -126.81 M |
| Levered Free Cash Flow (TTM) | -81.79 M |
| Return on Assets (TTM) | -20.40% |
| Return on Equity (TTM) | -26.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Cullinan Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
0.7
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.0 |
| Average | 0.70 |
|
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.49% |
| % Held by Institutions | 118.80% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (UBS, 149.58%) | Buy |
| Median | 29.00 (141.27%) | |
| Low | 28.00 (HC Wainwright & Co., 132.95%) | Buy |
| Average | 29.00 (141.27%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 16.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 24 Oct 2024 | 30.00 (149.58%) | Buy | 15.86 |
| HC Wainwright & Co. | 16 Oct 2024 | 28.00 (132.95%) | Buy | 17.61 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AHMED NADIM | - | 12.27 | -8,400 | -103,068 |
| Aggregate Net Quantity | -8,400 | |||
| Aggregate Net Value ($) | -103,068 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.27 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AHMED NADIM | Officer | 24 Dec 2024 | Sell (-) | 8,400 | 12.27 | 103,068 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |